The Gilead Sciences story
What drives Gilead Sciences, what its price assumes and what could change the story, written from its own filings.
- HIV funds the transition. In the quarter to June 2026, HIV sales rose 12% to $5.7 billion, led by Biktarvy and faster growth in Descovy.
- Acquisitions reshape earnings. Gilead reported a diluted loss of $8.45 per share in the quarter to June 2026 while generating $3.6 billion of operating cash flow, as acquired research expenses dominated earnings.
- Cancer remains uneven. In the quarter to June 2026, Trodelvy sales grew 26% to $457 million, while cell therapy sales declined 14% to $417 million amid competition.
